• Biohaven is enrolling patients in a pivotal Phase 3 trial of BHV-1300 for Graves' disease at more than 55 US and Canadian sites.
• The placebo-controlled study targets approximately 300 adults, assessing normal thyroid function at week 26 without antithyroid drugs.
• Earlier Phase 1b results showed reduced disease-driving autoantibodies and normalized thyroid hormones in patients who remained hyperthyroid despite antithyroid treatment.
• Three posters are being presented at the November 4-7, 2026, American Thyroid Association meeting, covering patient experience and preclinical BHV-1440 findings.
• Ono Pharmaceutical licensed the MoDE portfolio in selected Asian markets in October 2026 for $80 million upfront, with additional milestone payments and royalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE89780) on November 05, 2026, and is solely responsible for the information contained therein.